Skip to content

Application of peptamen in allogeneic Hematopoietic stem cell transplantation

The clinical study of peptamen in allogeneic Hematopoietic stem cell transplantation in children

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040995
Enrollment
Unknown
Registered
2020-12-16
Start date
2020-12-31
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemopathy

Interventions

experimental group:Taking PEPTAMEN JUNIOR
Blank control Group:Not taking PEPTAMEN JUNIOR

Sponsors

Children's Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 16 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis is clear and there are indications for an allogeneic Hematopoietic stem cell. 2. The liver function was normal, and ALT, AST <= 10 ULN and TBIL <= 5 ULN. Bun and CR <= 1.25 ULN. No Cardiac insufficiency was detected by ECG and echocardiography. 3. The patient's legal guardian has the desire and the request to carry on the allogeneic stem cell transplant treatment, and before the treatment signs the informed consent, the informed consent should inform its all clinical research related content, the patient is willing and obeys the treatment plan, follow-up schedules, lab tests.

Exclusion criteria

Exclusion criteria: 1. There are other diseases, such as serious impairment of important organ function: Respiratory Failure, cardiac insufficiency, decompensated hepatic insufficiency, renal insufficiency, etc. 2. Other drugs are being studied by clinical researchers. 3. Who are allergic to PEPTAMEN JUNIOP. 4. Patients with other severe acute or chronic physical or mental disorders, or laboratory abnormalities, may affect patient safety and compliance, informed consent, study participation, follow-up, or interpretation of results.

Design outcomes

Primary

MeasureTime frame
GVHD;chimerism;CBC;serum albumin;Prealbumin;Total protein;Liver function;Renal function;Time of granulocyte implantation;Platelet implantation time;Implantation rate;Body weight;Grip strength;Humoral immunity;Cellular immunity;Hospital stay in Laminar flow room;

Secondary

MeasureTime frame
12-month disease-free survival;6-month disease-free survival;Transplant-related mortality;

Countries

China

Contacts

Public ContactHu Shaoyan

Children's Hospital of Soochow University

hushaoyan@suda.edu.cn+86 0512 80692929

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026